http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 14 Jul 2026 06:05:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Alto+Neuroscience%2C+Inc.+++For%3A+Jul+13/26764287.html si-local-file:///var/storage/secattach/20260714/26764287.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Alto+Neuroscience%2C+Inc.+++For%3A+Jul+13/26764287.html Tue, 14 Jul 2026 06:05:00 -0400 ANRO O.61594251 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Alto+Neuroscience%2C+Inc.+++For%3A+Jul+13/26764287.html si-local-file:///var/storage/secattach/20260714/26764287.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Alto+Neuroscience%2C+Inc.+++For%3A+Jul+13/26764287.html Tue, 14 Jul 2026 06:05:00 -0400 ANRO O.61594251 http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Alto+Neuroscience%2C+Inc.++++++++++++++/26764269.html si-local-file:///var/storage/secattach/20260714/26764269.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Alto+Neuroscience%2C+Inc.++++++++++++++/26764269.html Tue, 14 Jul 2026 06:03:00 -0400 ANRO O.61594251 http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Alto+Neuroscience%2C+Inc.++++++++++++++/26764269.html si-local-file:///var/storage/secattach/20260714/26764269.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Alto+Neuroscience%2C+Inc.++++++++++++++/26764269.html Tue, 14 Jul 2026 06:03:00 -0400 ANRO O.61594251 http://www.streetinsider.com/Equity+Offerings/Alto+Neuroscience+prices+%24100M+stock+offering+to+fund+depression+trial/26759908.html <p>Alto Neuroscience, Inc. (NYSE: ANRO) has priced an underwritten registered direct offering of 3,776,436 shares of common stock at $26.48 per share, according to a company statement.</p> <p>The clinical-stage biopharmaceutical company expects gross proceeds of approximately $100.0 million before underwriting discounts, commissions, and estimated offering expenses. The offering is expected to close on July 14, 2026, subject to customary closing conditions.</p> <p>Alto Neuroscience said it intends to use the proceeds, combined with existing cash and cash equivalents, to accelerate and expand clinical development of its drug candidate ALTO-207. This includes funding an additional planned Phase 3 trial of ALTO-207 as a monotherapy http://www.streetinsider.com/Equity+Offerings/Alto+Neuroscience+prices+%24100M+stock+offering+to+fund+depression+trial/26759908.html Mon, 13 Jul 2026 07:47:16 -0400 A.09621214 A.21446405 A.50202048 ANRO O.00003925 O.32241120 O.51342647 O.61594251 http://www.streetinsider.com/Equity+Offerings/Alto+Neuroscience+prices+%24100M+stock+offering+to+fund+depression+trial/26759908.html <p>Alto Neuroscience, Inc. (NYSE: ANRO) has priced an underwritten registered direct offering of 3,776,436 shares of common stock at $26.48 per share, according to a company statement.</p> <p>The clinical-stage biopharmaceutical company expects gross proceeds of approximately $100.0 million before underwriting discounts, commissions, and estimated offering expenses. The offering is expected to close on July 14, 2026, subject to customary closing conditions.</p> <p>Alto Neuroscience said it intends to use the proceeds, combined with existing cash and cash equivalents, to accelerate and expand clinical development of its drug candidate ALTO-207. This includes funding an additional planned Phase 3 trial of ALTO-207 as a monotherapy http://www.streetinsider.com/Equity+Offerings/Alto+Neuroscience+prices+%24100M+stock+offering+to+fund+depression+trial/26759908.html Mon, 13 Jul 2026 07:47:16 -0400 A.09621214 A.21446405 A.50202048 ANRO O.00003925 O.32241120 O.51342647 O.61594251 http://www.streetinsider.com/Equity+Offerings/Alto+Neuroscience+prices+%24100M+stock+offering+to+fund+depression+trial/26759908.html <p>Alto Neuroscience, Inc. (NYSE: ANRO) has priced an underwritten registered direct offering of 3,776,436 shares of common stock at $26.48 per share, according to a company statement.</p> <p>The clinical-stage biopharmaceutical company expects gross proceeds of approximately $100.0 million before underwriting discounts, commissions, and estimated offering expenses. The offering is expected to close on July 14, 2026, subject to customary closing conditions.</p> <p>Alto Neuroscience said it intends to use the proceeds, combined with existing cash and cash equivalents, to accelerate and expand clinical development of its drug candidate ALTO-207. This includes funding an additional planned Phase 3 trial of ALTO-207 as a monotherapy http://www.streetinsider.com/Equity+Offerings/Alto+Neuroscience+prices+%24100M+stock+offering+to+fund+depression+trial/26759908.html Mon, 13 Jul 2026 07:47:16 -0400 A.09621214 A.21446405 A.50202048 ANRO O.00003925 O.32241120 O.51342647 O.61594251 http://www.streetinsider.com/Equity+Offerings/Alto+Neuroscience+prices+%24100M+stock+offering+to+fund+depression+trial/26759908.html <p>Alto Neuroscience, Inc. (NYSE: ANRO) has priced an underwritten registered direct offering of 3,776,436 shares of common stock at $26.48 per share, according to a company statement.</p> <p>The clinical-stage biopharmaceutical company expects gross proceeds of approximately $100.0 million before underwriting discounts, commissions, and estimated offering expenses. The offering is expected to close on July 14, 2026, subject to customary closing conditions.</p> <p>Alto Neuroscience said it intends to use the proceeds, combined with existing cash and cash equivalents, to accelerate and expand clinical development of its drug candidate ALTO-207. This includes funding an additional planned Phase 3 trial of ALTO-207 as a monotherapy http://www.streetinsider.com/Equity+Offerings/Alto+Neuroscience+prices+%24100M+stock+offering+to+fund+depression+trial/26759908.html Mon, 13 Jul 2026 07:47:16 -0400 A.09621214 A.21446405 A.50202048 ANRO O.00003925 O.32241120 O.51342647 O.61594251 http://www.streetinsider.com/Equity+Offerings/Alto+Neuroscience+prices+%24100M+stock+offering+to+fund+depression+trial/26759908.html <p>Alto Neuroscience, Inc. (NYSE: ANRO) has priced an underwritten registered direct offering of 3,776,436 shares of common stock at $26.48 per share, according to a company statement.</p> <p>The clinical-stage biopharmaceutical company expects gross proceeds of approximately $100.0 million before underwriting discounts, commissions, and estimated offering expenses. The offering is expected to close on July 14, 2026, subject to customary closing conditions.</p> <p>Alto Neuroscience said it intends to use the proceeds, combined with existing cash and cash equivalents, to accelerate and expand clinical development of its drug candidate ALTO-207. This includes funding an additional planned Phase 3 trial of ALTO-207 as a monotherapy http://www.streetinsider.com/Equity+Offerings/Alto+Neuroscience+prices+%24100M+stock+offering+to+fund+depression+trial/26759908.html Mon, 13 Jul 2026 07:47:16 -0400 A.09621214 A.21446405 A.50202048 ANRO O.00003925 O.32241120 O.51342647 O.61594251 http://www.streetinsider.com/Equity+Offerings/Alto+Neuroscience+prices+%24100M+stock+offering+to+fund+depression+trial/26759908.html <p>Alto Neuroscience, Inc. (NYSE: ANRO) has priced an underwritten registered direct offering of 3,776,436 shares of common stock at $26.48 per share, according to a company statement.</p> <p>The clinical-stage biopharmaceutical company expects gross proceeds of approximately $100.0 million before underwriting discounts, commissions, and estimated offering expenses. The offering is expected to close on July 14, 2026, subject to customary closing conditions.</p> <p>Alto Neuroscience said it intends to use the proceeds, combined with existing cash and cash equivalents, to accelerate and expand clinical development of its drug candidate ALTO-207. This includes funding an additional planned Phase 3 trial of ALTO-207 as a monotherapy http://www.streetinsider.com/Equity+Offerings/Alto+Neuroscience+prices+%24100M+stock+offering+to+fund+depression+trial/26759908.html Mon, 13 Jul 2026 07:47:16 -0400 A.09621214 A.21446405 A.50202048 ANRO O.00003925 O.32241120 O.51342647 O.61594251 http://www.streetinsider.com/Equity+Offerings/Alto+Neuroscience+prices+%24100M+stock+offering+to+fund+depression+trial/26759908.html <p>Alto Neuroscience, Inc. (NYSE: ANRO) has priced an underwritten registered direct offering of 3,776,436 shares of common stock at $26.48 per share, according to a company statement.</p> <p>The clinical-stage biopharmaceutical company expects gross proceeds of approximately $100.0 million before underwriting discounts, commissions, and estimated offering expenses. The offering is expected to close on July 14, 2026, subject to customary closing conditions.</p> <p>Alto Neuroscience said it intends to use the proceeds, combined with existing cash and cash equivalents, to accelerate and expand clinical development of its drug candidate ALTO-207. This includes funding an additional planned Phase 3 trial of ALTO-207 as a monotherapy http://www.streetinsider.com/Equity+Offerings/Alto+Neuroscience+prices+%24100M+stock+offering+to+fund+depression+trial/26759908.html Mon, 13 Jul 2026 07:47:16 -0400 A.09621214 A.21446405 A.50202048 ANRO O.00003925 O.32241120 O.51342647 O.61594251 http://www.streetinsider.com/Equity+Offerings/Alto+Neuroscience+prices+%24100M+stock+offering+to+fund+depression+trial/26759908.html <p>Alto Neuroscience, Inc. (NYSE: ANRO) has priced an underwritten registered direct offering of 3,776,436 shares of common stock at $26.48 per share, according to a company statement.</p> <p>The clinical-stage biopharmaceutical company expects gross proceeds of approximately $100.0 million before underwriting discounts, commissions, and estimated offering expenses. The offering is expected to close on July 14, 2026, subject to customary closing conditions.</p> <p>Alto Neuroscience said it intends to use the proceeds, combined with existing cash and cash equivalents, to accelerate and expand clinical development of its drug candidate ALTO-207. This includes funding an additional planned Phase 3 trial of ALTO-207 as a monotherapy http://www.streetinsider.com/Equity+Offerings/Alto+Neuroscience+prices+%24100M+stock+offering+to+fund+depression+trial/26759908.html Mon, 13 Jul 2026 07:47:16 -0400 A.09621214 A.21446405 A.50202048 ANRO O.00003925 O.32241120 O.51342647 O.61594251 http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Announces+Pricing+of+%24100.0+Million+Underwritten+Registered+Direct+Offering+of+Common+Stock/26759907.html <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options, announced today the pricing of an underwritten registered direct offering of 3,776,436 shares of its common stock at a price of $26.48 per share. All of the shares are being offered by Alto. The gross proceeds from the offering are expected to be approximately $100.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. The offering is expected to close on July 14, 2026, http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Announces+Pricing+of+%24100.0+Million+Underwritten+Registered+Direct+Offering+of+Common+Stock/26759907.html Mon, 13 Jul 2026 07:47:00 -0400 A.09621214 A.21446405 A.50202048 ANRO O.00003925 O.32241120 O.51342647 O.61594251 http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Announces+Pricing+of+%24100.0+Million+Underwritten+Registered+Direct+Offering+of+Common+Stock/26759907.html <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options, announced today the pricing of an underwritten registered direct offering of 3,776,436 shares of its common stock at a price of $26.48 per share. All of the shares are being offered by Alto. The gross proceeds from the offering are expected to be approximately $100.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. The offering is expected to close on July 14, 2026, http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Announces+Pricing+of+%24100.0+Million+Underwritten+Registered+Direct+Offering+of+Common+Stock/26759907.html Mon, 13 Jul 2026 07:47:00 -0400 A.09621214 A.21446405 A.50202048 ANRO O.00003925 O.32241120 O.51342647 O.61594251 http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Announces+Pricing+of+%24100.0+Million+Underwritten+Registered+Direct+Offering+of+Common+Stock/26759907.html <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options, announced today the pricing of an underwritten registered direct offering of 3,776,436 shares of its common stock at a price of $26.48 per share. All of the shares are being offered by Alto. The gross proceeds from the offering are expected to be approximately $100.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. The offering is expected to close on July 14, 2026, http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Announces+Pricing+of+%24100.0+Million+Underwritten+Registered+Direct+Offering+of+Common+Stock/26759907.html Mon, 13 Jul 2026 07:47:00 -0400 A.09621214 A.21446405 A.50202048 ANRO O.00003925 O.32241120 O.51342647 O.61594251 http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Announces+Pricing+of+%24100.0+Million+Underwritten+Registered+Direct+Offering+of+Common+Stock/26759907.html <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options, announced today the pricing of an underwritten registered direct offering of 3,776,436 shares of its common stock at a price of $26.48 per share. All of the shares are being offered by Alto. The gross proceeds from the offering are expected to be approximately $100.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. The offering is expected to close on July 14, 2026, http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Announces+Pricing+of+%24100.0+Million+Underwritten+Registered+Direct+Offering+of+Common+Stock/26759907.html Mon, 13 Jul 2026 07:47:00 -0400 A.09621214 A.21446405 A.50202048 ANRO O.00003925 O.32241120 O.51342647 O.61594251 http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Announces+Pricing+of+%24100.0+Million+Underwritten+Registered+Direct+Offering+of+Common+Stock/26759907.html <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options, announced today the pricing of an underwritten registered direct offering of 3,776,436 shares of its common stock at a price of $26.48 per share. All of the shares are being offered by Alto. The gross proceeds from the offering are expected to be approximately $100.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. The offering is expected to close on July 14, 2026, http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Announces+Pricing+of+%24100.0+Million+Underwritten+Registered+Direct+Offering+of+Common+Stock/26759907.html Mon, 13 Jul 2026 07:47:00 -0400 A.09621214 A.21446405 A.50202048 ANRO O.00003925 O.32241120 O.51342647 O.61594251 http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Announces+Pricing+of+%24100.0+Million+Underwritten+Registered+Direct+Offering+of+Common+Stock/26759907.html <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options, announced today the pricing of an underwritten registered direct offering of 3,776,436 shares of its common stock at a price of $26.48 per share. All of the shares are being offered by Alto. The gross proceeds from the offering are expected to be approximately $100.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. The offering is expected to close on July 14, 2026, http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Announces+Pricing+of+%24100.0+Million+Underwritten+Registered+Direct+Offering+of+Common+Stock/26759907.html Mon, 13 Jul 2026 07:47:00 -0400 A.09621214 A.21446405 A.50202048 ANRO O.00003925 O.32241120 O.51342647 O.61594251 http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Announces+Pricing+of+%24100.0+Million+Underwritten+Registered+Direct+Offering+of+Common+Stock/26759907.html <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options, announced today the pricing of an underwritten registered direct offering of 3,776,436 shares of its common stock at a price of $26.48 per share. All of the shares are being offered by Alto. The gross proceeds from the offering are expected to be approximately $100.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. The offering is expected to close on July 14, 2026, http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Announces+Pricing+of+%24100.0+Million+Underwritten+Registered+Direct+Offering+of+Common+Stock/26759907.html Mon, 13 Jul 2026 07:47:00 -0400 A.09621214 A.21446405 A.50202048 ANRO O.00003925 O.32241120 O.51342647 O.61594251 http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Announces+Pricing+of+%24100.0+Million+Underwritten+Registered+Direct+Offering+of+Common+Stock/26759907.html <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options, announced today the pricing of an underwritten registered direct offering of 3,776,436 shares of its common stock at a price of $26.48 per share. All of the shares are being offered by Alto. The gross proceeds from the offering are expected to be approximately $100.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. The offering is expected to close on July 14, 2026, http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Announces+Pricing+of+%24100.0+Million+Underwritten+Registered+Direct+Offering+of+Common+Stock/26759907.html Mon, 13 Jul 2026 07:47:00 -0400 A.09621214 A.21446405 A.50202048 ANRO O.00003925 O.32241120 O.51342647 O.61594251 http://www.streetinsider.com/Business+Wire/Alto+Neuroscience+Announces+Pricing+of+%24100.0+Million+Underwritten+Registered+Direct+Offering+of+Common+Stock/26759907.html <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options, announced today the pricing of an underwritten registered direct offering of 3,776,436 shares of its common stock at a price of $26.48 per share. All of the shares are being offered by Alto. The gross proceeds from the offering are expected to be approximately $100.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. The offering is expected to close on July 14, 2026, http://www.streetinsider.com/Business+Wire/Alto+Neuroscience+Announces+Pricing+of+%24100.0+Million+Underwritten+Registered+Direct+Offering+of+Common+Stock/26759907.html Mon, 13 Jul 2026 07:47:00 -0400 A.09621214 A.21446405 A.50202048 ANRO O.00003925 O.32241120 O.51342647 O.61594251 http://www.streetinsider.com/Business+Wire/Alto+Neuroscience+Announces+Pricing+of+%24100.0+Million+Underwritten+Registered+Direct+Offering+of+Common+Stock/26759907.html <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options, announced today the pricing of an underwritten registered direct offering of 3,776,436 shares of its common stock at a price of $26.48 per share. All of the shares are being offered by Alto. The gross proceeds from the offering are expected to be approximately $100.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. The offering is expected to close on July 14, 2026, http://www.streetinsider.com/Business+Wire/Alto+Neuroscience+Announces+Pricing+of+%24100.0+Million+Underwritten+Registered+Direct+Offering+of+Common+Stock/26759907.html Mon, 13 Jul 2026 07:47:00 -0400 A.09621214 A.21446405 A.50202048 ANRO O.00003925 O.32241120 O.51342647 O.61594251 http://www.streetinsider.com/Business+Wire/Alto+Neuroscience+Announces+Pricing+of+%24100.0+Million+Underwritten+Registered+Direct+Offering+of+Common+Stock/26759907.html <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options, announced today the pricing of an underwritten registered direct offering of 3,776,436 shares of its common stock at a price of $26.48 per share. All of the shares are being offered by Alto. The gross proceeds from the offering are expected to be approximately $100.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. The offering is expected to close on July 14, 2026, http://www.streetinsider.com/Business+Wire/Alto+Neuroscience+Announces+Pricing+of+%24100.0+Million+Underwritten+Registered+Direct+Offering+of+Common+Stock/26759907.html Mon, 13 Jul 2026 07:47:00 -0400 A.09621214 A.21446405 A.50202048 ANRO O.00003925 O.32241120 O.51342647 O.61594251 http://www.streetinsider.com/Business+Wire/Alto+Neuroscience+Announces+Pricing+of+%24100.0+Million+Underwritten+Registered+Direct+Offering+of+Common+Stock/26759907.html <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options, announced today the pricing of an underwritten registered direct offering of 3,776,436 shares of its common stock at a price of $26.48 per share. All of the shares are being offered by Alto. The gross proceeds from the offering are expected to be approximately $100.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. The offering is expected to close on July 14, 2026, http://www.streetinsider.com/Business+Wire/Alto+Neuroscience+Announces+Pricing+of+%24100.0+Million+Underwritten+Registered+Direct+Offering+of+Common+Stock/26759907.html Mon, 13 Jul 2026 07:47:00 -0400 A.09621214 A.21446405 A.50202048 ANRO O.00003925 O.32241120 O.51342647 O.61594251 http://www.streetinsider.com/Business+Wire/Alto+Neuroscience+Announces+Pricing+of+%24100.0+Million+Underwritten+Registered+Direct+Offering+of+Common+Stock/26759907.html <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options, announced today the pricing of an underwritten registered direct offering of 3,776,436 shares of its common stock at a price of $26.48 per share. All of the shares are being offered by Alto. The gross proceeds from the offering are expected to be approximately $100.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. The offering is expected to close on July 14, 2026, http://www.streetinsider.com/Business+Wire/Alto+Neuroscience+Announces+Pricing+of+%24100.0+Million+Underwritten+Registered+Direct+Offering+of+Common+Stock/26759907.html Mon, 13 Jul 2026 07:47:00 -0400 A.09621214 A.21446405 A.50202048 ANRO O.00003925 O.32241120 O.51342647 O.61594251